Search
Search Funnelback University
- Refined by:
- Date: 2022
11 -
60 of
178
search results for `news stories` |u:www.enterprise.cam.ac.uk
Fully-matching results
-
Academic consultancy services – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/for-the-university/be-a-consultant/22 Mar 2022: Academic consultancy is a key way in which the University shares its knowledge and expertise with government, industry and the public sector. -
Celebrating University research to commercial reality – Cambridge…
https://www.enterprise.cam.ac.uk/celebrating-university-research-to-commercial-reality/30 Sep 2022: Between the stories told in the showcase, and the conversations between the guests, the overriding sense from the evening was one of passion and collaboration. -
The Chris Abell Postdoc Business Plan Competition 2022 – Cambridge…
https://www.enterprise.cam.ac.uk/events/the-chris-abell-postdoc-business-plan-competition-2022/3 May 2022: The Chris Abell Postdoc Business Plan Competition is a programme designed to help accelerate the creation of businesses from University research. -
Powering a green revolution – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/powering-a-green-revolution/23 May 2022: Interview with Dr Giorgia Longobardi, CEO of Cambridge GaN Devices, whose range of power devices herald a new era of greener electronics. -
From sick-care to health-care – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/from-sick-care-to-health-care/9 Feb 2022: Interview with Dr Gita Khalili Moghaddam whose technology aims to help keep people healthy by intervening early to avoid hospitalisation. -
Science and Technology Facilities Council (STFC) Follow-on Fund (FoF) …
https://www.enterprise.cam.ac.uk/grant/science-and-technology-facilities-council-stfc-follow-on-fund-fof/18 Jan 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Science and Technology Facilities Council (STFC) Follow-on Fund (FoF). FoF is designed to fund a short term proof-of-concept project, which could lead on to further commercial -
Our Cambridge connections – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/about/our-role-within-the-cambridge-ecosystem/beyond-the-university/25 Jan 2022: We nurture close connections and strong working relationships with a broad range of stakeholders in the wider Cambridge ecosystem. -
Can commercialisation lead to better impact outcomes for policy…
https://www.enterprise.cam.ac.uk/can-commercialisation-lead-to-better-impact-outcomes-for-policy-research/16 Dec 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. 16 December 2022. Can commercialisation lead to better impact outcomes for policy research? Share:. We asked our participants whether a research commercialisation approach or -
Challenges and Opportunities for Commercialisation of Research out of …
https://www.enterprise.cam.ac.uk/challenges-and-opportunities-for-commercialisation-of-research-out-of-the-social-sciences/25 Oct 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. 26 October 2022. Challenges and Opportunities for Commercialisation of Research out of the Social Sciences. Share:. I was delighted to join Cambridge Enterprise as a Project Associate -
New approach to ‘cosmic magnet’ manufacturing could reduce reliance…
https://www.enterprise.cam.ac.uk/new-approach-to-cosmic-magnet-manufacturing-could-reduce-reliance-on-rare-earths-in-low-carbon-technologies/25 Oct 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. 25 October 2022. New approach to ‘cosmic magnet’ manufacturing could reduce reliance on rare earths in low-carbon technologies. Share:. Achieving high performance tetrataenite -
Impact Insight: Xampla – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/impact-insight-xampla/12 May 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Impact Insight: Xampla. Share:. Impact Insight video case study: Xampla. The first in our series of Impact Insight videos focuses on Xampla. It tells the exciting story of the research -
New financing round for PneumaCare – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/pneumacare-completes-new-financing-round/1 Feb 2022: PneumaCare has worked closely with another of its investors, Plextek Ltd, to use 3D motion capture technology in its lead product. Read more here. -
Murid herpesvirus-4 (MuHV 4) Antibodies - Cambridge Enterprise
https://www.enterprise.cam.ac.uk/reagents/murid-herpes-virus-4-antibodies/9 May 2022: Mouse monoclonal antibodies raised against Murid herpesvirus-4 (MuHV 4) developed at the University of Cambridge. -
DIOSynVax: tackling COVID-19 – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/diosynvax-tackling-covid-19/11 Apr 2022: Case study of DIOSynVax, a University of Cambridge spin-out founded by Professor Heeney, which is developing a vaccine for COVID-19. -
CRoSS Programme: Research Impact Ideation Workshop – Cambridge…
https://www.enterprise.cam.ac.uk/events/cross-programme-research-impact-ideation-workshop-2/2 Dec 2022: Creating innovative proposals which could be used to translate academic insight into a tangible real-world outcomes. -
Develop a commercial opportunity – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/for-the-university/develop-a-commercial-opportunity/19 Jan 2022: We help University of Cambridge members commercialise their research by transforming their ideas into attractive opportunities. -
Science and Technology Facilities Council (STFC) Knowledge Exchange…
https://www.enterprise.cam.ac.uk/grant/science-and-technology-facilities-council-stfc-knowledge-exchange-and-commercialisation-kec-fellowships/18 Jan 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Science and Technology Facilities Council (STFC) Knowledge Exchange and Commercialisation (KEC) Fellowships. The KEC Fellowship scheme is designed to facilitate the development of -
The University of Cambridge ecosystem – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/about/our-role-within-the-cambridge-ecosystem/within-the-university/20 Jul 2022: We work closely with University members to help them create impact from their research through knowledge and technology transfer. -
Impact Insight: iKVA – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/impact-insight-ikva/12 May 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Impact Insight: iKVA. Share:. This Impact Insight video tells the story behind the creation of iKVA. iKVA is a University of Cambridge spin-out that uses artificial intelligence (AI) to -
New Head at Cambridge Enterprise Seed Funds – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/new-head-at-cambridge-enterprise-seed-funds/6 Apr 2022: Cambridge Enterprise, the commercialisation arm of the University of Cambridge, announces the appointment of Dr Christine Martin as Head of Seed Funds. -
KARPAS 25 Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-25-human-myeloma-cell-line/9 May 2022: KARPAS 25 Human Myeloma cell line useful in oncology research, developed at the University of Cambridge. -
Impact Insight video case study: Xampla – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/impact-insight-video-case-study-xampla/15 Mar 2022: The first in our new series of Impact Insight videos focuses on the exciting research commercialisation story behind Xampla. -
Research tools licensing – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/for-the-university/develop-a-commercial-opportunity/research-tools/19 Dec 2022: We have been licensing research tools for over a decade and can therefore fully support you through the process. -
Impact Insight: Versed AI – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/impact-insight-versed-ai/12 May 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Impact Insight: Versed AI. Share:. Impact Insight video case study: Versed AI. The second in our Impact Insight video series focuses on Versed AI. It tells the story behind the creation -
KARPAS 417 Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-417-human-myeloma-cell-line/9 May 2022: KARPAS 417 Human Myeloma cell line useful in oncology research, developed at the University of Cambridge. -
TenU receives £4 million to boost research commercialisation –…
https://www.enterprise.cam.ac.uk/news/tenu-receives-4-million-to-boost-research-commercialisation/18 Aug 2022: International research commercialisation collaboration TenU receives £4m funding boost -
Impact Insight video case study: iKVA – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/impact-insight-video-case-study-ikva/23 Mar 2022: The story behind the creation of iKVA, a University of Cambridge spin-out that uses AI to facilitate knowledge management for multinationals. -
Impact Insight: Kalamna CIC – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/impact-insight-kalamna-cic/12 May 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Impact Insight: Kalamna CIC. Share:. Impact Insight video case study: Kalamna toolkit. The third in our Impact Insight video series focuses on the licensing of the Kalamna toolkit for -
KARPAS 929 Human Myeloma cell line - Cambridge Enterprise
https://www.enterprise.cam.ac.uk/reagents/karpas-929-human-myeloma-cell-line/9 May 2022: KARPAS 929 Human Myeloma cell line, developed at the University of Cambridge, useful in oncology research. -
£1.5m seed funding for Cambridge spin-out iKVA – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/university-of-cambridge-spin-out-ikva-secures-1-5m-seed-funding/2 Feb 2022: University of Cambridge spin-out iKVA has secured £1.5m in seed funding to begin the rollout of its unique AI technology. -
Realising the market potential of software – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/for-the-university/develop-a-commercial-opportunity/realising-the-market-potential-of-software/18 Jul 2022: Related news and case studies. Pause. Play. Review our answers to your most frequently asked questions. -
Impact Insight video case study: Versed AI – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/impact-insight-video-case-study-versed-ai/15 Mar 2022: The second in our new series of Impact Insight videos focuses on the exciting research commercialisation story behind Versed AI. -
Watch our #nextgreatidea film – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/watch-our-nextgreatidea-film/15 Feb 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Watch our #nextgreatidea film. Share:. Our film is a distinctive take on innovation that showcases some of the world-changing ideas we have supported in the journey to market – from a -
KARPAS 707H Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-707h-human-myeloma-cell-line/9 May 2022: KARPAS 707H Human myeloma cell line suitable for the generation of stable human hybridomas for the creation of fully human monoclonal antibodies. -
Finalists announced in 2022 Chris Abell Postdoc Business Plan…
https://www.enterprise.cam.ac.uk/news/finalists-announced-in-2022-chris-abell-postdoc-business-plan-competition/4 Oct 2022: Six finalists announced for the 2022 Chris Abell Postdoc Business Plan Competition. -
Ceres Agri-Tech Partnership – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/ceres-a-rich-harvest-of-agri-tech-projects/11 Apr 2022: This initiative links the Universities of Cambridge, Lincoln, Reading, Hertfordshire, and East Anglia to drive commercialisation of agri-tech research and innovation. -
Creative Cambridge 2022 highlights – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/creative-cambridge-2022-highlights/18 Aug 2022: More on Creative Cambridge. Discover Creative Cambridge. Learn more about our Creative Cambridge initiative, sign up to our dedicated newsletter to keep informed about forthcoming events and news for the creative -
KARPAS 1272 Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-1272-human-myeloma-cell-line/9 May 2022: KARPAS 1272 Human Myeloma cell line, useful in oncology research, developed at the University of Cambridge. -
The journey of a University idea – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/for-the-university/develop-a-commercial-opportunity/the-journey-of-a-university-idea/10 May 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. The journey of a University idea. How to make your commercial idea thrive. You have come up with an exciting commercial idea – but what do you do next? The diagram below gives an -
Semi-finalists announced in 2022 Chris Abell Postdoc Business Plan…
https://www.enterprise.cam.ac.uk/news/semi-finalists-announced-in-2022-chris-abell-postdoc-business-plan-competition/17 Aug 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. 28 July 2022. Semi-finalists announced in 2022 Chris Abell Postdoc Business Plan Competition. Share:. This year’s Chris Abell Postdoc Business Plan Competition is sponsored byand -
Nyobolt: Supercharging the electric revolution – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/nyobolt-supercharging-the-electric-revolution/11 Apr 2022: Nyobolt is a University spin out from the Yusuf Hamied Department of Chemistry, commercialising a novel ultra-high power battery technology -
KARPAS 241 Human Monoblastic cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-241-human-monoblastic-cell-line/9 May 2022: KARPAS 241 Human Monoblastic cell line useful in oncology research, developed at the University of Cambridge. -
Sustainability, investment and the Carbon Challenge – Cambridge…
https://www.enterprise.cam.ac.uk/video/sustainability-investment-and-the-carbon-challenge/12 Oct 2022: Chris Gibbs shares his perspectives on the importance of sustainability, investing in sustainability businesses and building entrepreneurial mindsets through the Carbon Challenge. -
Sparxell wins the 2022 Chris Abell Postdoc Business Plan Competition…
https://www.enterprise.cam.ac.uk/news/sparxell-wins-the-2022-chris-abell-postdoc-business-plan-competition/11 Nov 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. 11 November 2022. Sparxell wins the 2022 Chris Abell Postdoc Business Plan Competition. Share:. Sparxell has won the Chris Abell Postdoc Business Plan Competition 2022, securing the £20 -
Impact Insight video case study: Kalamna toolkit – Cambridge…
https://www.enterprise.cam.ac.uk/case-studies/impact-insight-video-case-study-kalamna-toolkit/15 Mar 2022: Kalamna, a University of Cambridge social enterprise, has developed an innovative phonics-based toolkit for learning Arabic. -
CAM2 software for hearing aid fitting – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/reagents/cam2-software-for-hearing-aid-fitting/9 May 2022: CAM2 software is a package that enables hearing aids to be tailored to an individual’s needs, resulting in improved hearing quality. -
Cambridge joins $72.5m round launching mitochondrial therapies…
https://www.enterprise.cam.ac.uk/news/cambridge-joins-72-5m-round-launching-mitochondrial-therapies-pioneer-pretzel/19 Sep 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. 12 September 2022. Cambridge joins $72.5m round launching mitochondrial therapies pioneer Pretzel. Share:. a biotechnology company harnessing the intricacies of mitochondrial biology to -
Case study: Futures We Want – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/consultancy-services-determining-the-futures-we-want/11 Apr 2022: Evidence included scientific papers, government reports, and local news articles. The close collaboration with local expert teams throughout the process brought great depth of knowledge, and ensured that visions remained focused -
Human CD59 monoclonal antibody YTH 53.1
https://www.enterprise.cam.ac.uk/reagents/human-cd59-monoclonal-antibody-yth-53-1/9 May 2022: Hybridoma cell line producing YTH 53.1 antibodies raised against human CD59 which are rat monoclonal antibodies of the IgG2b isotype. -
Human CD7 monoclonal antibody YTH 30.15
https://www.enterprise.cam.ac.uk/reagents/human-cd7-monoclonal-antibody-yth-30-15/9 May 2022: Hybridoma cell line producing YTH 30.15 antibodies raised against human CD7 which are rat monoclonal antibodies of the IgG2b isotype.
Search history
Recently clicked results
Recently clicked results
Your click history is empty.
Recent searches
Recent searches
Your search history is empty.